Bristol Myers: thumbs up from CHMP for Opdivo

(CercleFinance.com) - Bristol Myers Squibb announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of Opdivo (nivolumab), in combination with cisplatin and gemcitabine, as first-line treatment for adult patients with unresectable or metastatic urothelial carcinoma.


The European Commission (EC), which has the power to approve medicines for the European Union (EU), will now re-examine the CHMP recommendation. The EC's final decision is expected in June 2024.

With this positive CHMP opinion, we are one step closer to providing eligible patients with unresectable or metastatic urothelial carcinoma in the European Union with a new first-line treatment option, Bristol Myers Squibb said.


Copyright (c) 2024 CercleFinance.com. All rights reserved.